åŸææ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Soligenix, Inc. ã¯ãç±³åœã§åžå°çŸæ£ãæ²»çããããã®è£œåã®éçºãšåååã«æ³šåããŠããŸããå瀟ã¯ãç¹æ®ãã€ãªã»ã©ãã¥ãŒãã£ã¯ã¹ãšå
¬è¡è¡çãœãªã¥ãŒã·ã§ã³ã® 2 ã€ã®ã»ã°ã¡ã³ãã§äºæ¥ãå±éããŠããŸããç¹æ®ãã€ãªã»ã©ãã¥ãŒãã£ã¯ã¹ ã»ã°ã¡ã³ãã§ã¯ãç®è T 现èãªã³ãè
«ã®æ²»çãç®çãšãã第 III çžèšåºè©Šéšãå®äºããæ°ããå
ç·ååŠçæ³ã® SGX301 ãšãé é žéšããã®å£è
ç²èçãæ²»çããããã®ç¬¬ III çžèšåºè©Šéšäžã®èªç¶é²åŸ¡èª¿ç¯æè¡ã§ãã SGX942 ãéçºããŠããŸãããã®ã»ã°ã¡ã³ãã§ã¯ãå°å
ã¯ããŒã³ç
çšã® SGX203 ãæ¥æ§æŸå°ç·è
žççšã® SGX201 ãªã©ãé床ã®ççãç¹åŸŽãšããèè
žé害ã®äºé²/æ²»çãç®çãšãã第 I/II çžèšåºè©Šéšãå®äºããçµå£ãã¯ãã¡ã¿ãŸã³ 17,21-ãžããããªããŒãã®ç¬èªè£œå€ãæäŸããŠããŸãããããªãã¯ãã«ã¹ãœãªã¥ãŒã·ã§ã³éšéã¯ã第Iaçžããã³ç¬¬Ibçžèšåºè©Šéšãå®äºãããªã·ã³æ¯çŽ ã¯ã¯ãã³åè£ã®RiVaxãæçç©è³ªèæ§ããã³æ°èææçã®æ²»çãç®çãšããåèšåºæ®µéã«ããé¡éŒ»çœæ²»çåè£ã®SGX943ãç±å®å®åã¯ã¯ãã³ã®åèšåºéçºæ®µéã«ããæè¡ThermoVaxãããã³COVID-19äºé²ãç®çãšããåèšåºéçºæ®µéã«ããã¯ã¯ãã³åè£ã®CiVaxã®éçºã«æºãã£ãŠããŸããå瀟ã¯ä»¥åã¯DOR BioPharma, Inc.ãšããŠç¥ãããŠããŸãããã2009幎ã«Soligenix, Inc.ã«ç€Ÿåã倿ŽããŸãããSoligenix, Inc.ã¯1987幎ã«èšç«ããããã¥ãŒãžã£ãŒãžãŒå·ããªã³ã¹ãã³ã«æ¬ç€Ÿã眮ããŠããŸãã